Last 18 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.18 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.66 | 0.93 | 0.51 | 0.50 | 1.04 | 2.03 | 3.34 | 2.35 | 1.49 | 0.96 | 1.44 | 1.76 | 1.76 |
| — | -54.2% | -84.7% | -78.7% | -30.2% | +111.1% | +131.5% | +33.5% | -15.4% | -13.4% | +38.6% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -79.3% | -15.4% | -28.3% | -28.7% | -17.4% | -14.6% | -17.0% | -12.5% | -16.6% | -17.1% | -12.5% | -9.5% | -8.0% |
| — | -5.2% | -67.0% | -128.9% | -4.4% | +14.3% | -35.6% | -32.3% | -107.6% | -84.7% | -17.7% | +35.4% | -53.0% | |
| ROA | -61.2% | -12.3% | -20.1% | -21.7% | -13.9% | -11.8% | -14.1% | -10.3% | -12.7% | -13.4% | -10.2% | -7.8% | -7.0% |
| — | -4.9% | -42.1% | -110.8% | -9.2% | +12.6% | -38.8% | -32.0% | -80.9% | -58.7% | -6.7% | +41.1% | -43.7% | |
| ROIC | -108.1% | -30.5% | -29.8% | -30.4% | -18.1% | -15.6% | -26.3% | -26.4% | -48.4% | -96.9% | -74.0% | -61.9% | -131.9% |
| — | -95.3% | -13.2% | -15.5% | +62.7% | +83.9% | +64.4% | +57.4% | +63.3% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 55.2% YoY to 13.15x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.11 | 0.25 | 0.20 | 0.16 | 0.14 | 0.13 | 0.11 | 0.19 | 0.16 | 0.15 | 0.13 | 0.14 |
| — | -22.8% | +100.5% | +80.2% | -15.2% | -14.7% | -13.7% | -16.6% | +35.8% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.41 | 13.15 | 4.74 | 4.95 | 7.41 | 8.47 | 7.45 | 15.78 | 6.43 | 6.35 | 8.88 | 9.35 | 9.88 |
| — | +55.2% | -36.5% | -68.7% | +15.3% | +33.3% | -16.1% | +68.8% | -35.0% | -51.7% | -19.3% | +19.9% | -27.1% | |
| Quick Ratio | 7.41 | 13.15 | 4.74 | 4.95 | 7.41 | 8.47 | 7.45 | 15.78 | 6.43 | 6.35 | 8.88 | 9.35 | 9.88 |
| — | +55.2% | -36.5% | -68.7% | +15.3% | +33.3% | -16.1% | +68.8% | -35.0% | -52.8% | -20.5% | +17.8% | -27.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 18 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonPepGen Inc.'s current P/E is -2.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking PepGen Inc.'s business trajectory between earnings reports.